Hot Features
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tu... SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK’s WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.395 | 18.3794466403 | 7.59 | 9.315 | 7.46 | 8670987 | 8.33516402 | CS |
| 4 | 0.855 | 10.5166051661 | 8.13 | 9.51 | 7.07 | 8419806 | 8.44942683 | CS |
| 12 | 4.655 | 107.505773672 | 4.33 | 9.51 | 4.02 | 7412477 | 7.06118935 | CS |
| 26 | 6.205 | 223.201438849 | 2.78 | 9.51 | 2.62 | 8053387 | 5.49563299 | CS |
| 52 | 7.265 | 422.38372093 | 1.72 | 9.51 | 1.39 | 5739378 | 4.3657358 | CS |
| 156 | 7.295 | 431.656804734 | 1.69 | 9.51 | 0.4986 | 2708479 | 3.45551051 | CS |
| 260 | -4.495 | -33.3456973294 | 13.48 | 15.0789 | 0.4986 | 1729335 | 3.54222888 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.